Trial intelligence / Profile preview

Chronocort vs Standard Glucocorticoid Therapy in Congenital Adrenal Hyperplasia

NCT02716818Phase 3Completed

Sponsor
Neurocrine Biosciences
Start
Feb 2016
Primary completion
Jul 2018
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Started Feb 2016; status: completed.

02

Drugs

hydrocortisone modified-release
03

Conditions

congenital adrenal hyperplasia (CAH)

Beyond the preview

Go deeper on NCT02716818.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02716818.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call